{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.89","upperLimit":"25.08","value":"11.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Week 48: Diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.89","upperLimit":"25.08","value":"11.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Week 60: Diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.89","upperLimit":"25.08","value":"11.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Week 72: Diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.11","upperLimit":"26.06","value":"11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Week 48: Pre-diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.37","upperLimit":"32.81","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Week 60: Pre-diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.75","upperLimit":"22.47","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Week 72: Pre-diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.81","upperLimit":"60.01","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Week 48: Non-diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.81","upperLimit":"60.01","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Week 60: Non-diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.81","upperLimit":"60.01","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Week 72: Non-diabetic"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Percentage of participants achieving IGF-1 \\<ULN at week 46, 60 and 72 overall by baseline diabetic status","dispersionType":"95% Confidence Interval","groups":[{"description":"These are the participants in the extension phase who received Pasireotide LAR","id":"OG000","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.","reportingStatus":"POSTED","timeFrame":"Weeks 48, 60, 72","title":"Extension Phase: Percentage of Participants With Mean GH < 1 μg/L and IGF-1 < ULN at Weeks 48, 60 and 72 (Overall by Baseline Diabetic Status)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}